Peter Bader1, Thomas Klingebiel2. 1. Klinik für Kinder- und Jugendmedizin, Schwerpunkt Stammzelltransplantation und Immunologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland. peter.bader@kgu.de. 2. Klinik für Kinder- und Jugendmedizin, Schwerpunkt Stammzelltransplantation und Immunologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland.
Abstract
BACKGROUND: Acute lymphatic leukemia is the most common malignant disease in children. Despite a good prognosis, new therapeutic concepts are needed for patients with refractory and relapsed disease. QUESTION: The importance of chimeric antigen receptor (CAR) T‑cell therapy for patients with refractory and post-stem cell transplantation. MATERIAL AND METHODS: Overview of studies in childhood; presentation of extraction, use, side effects and prognostic factors. RESULTS: In 30 patients with a leukemia burden of <5% at the time of lymphocytic chemotherapy, the probability of event-free survival after 12 months was 0.70; in patients with a leukemia burden of >5%, the probability of event-free survival was only 0.23. CONCLUSIONS: Further improvements in vector design will help to improve the effectiveness of this treatment. It will become important to isolate factors that will make it possible to identify patients who will respond to this therapy in the long term.
BACKGROUND:Acute lymphatic leukemia is the most common malignant disease in children. Despite a good prognosis, new therapeutic concepts are needed for patients with refractory and relapsed disease. QUESTION: The importance of chimeric antigen receptor (CAR) T‑cell therapy for patients with refractory and post-stem cell transplantation. MATERIAL AND METHODS: Overview of studies in childhood; presentation of extraction, use, side effects and prognostic factors. RESULTS: In 30 patients with a leukemia burden of <5% at the time of lymphocytic chemotherapy, the probability of event-free survival after 12 months was 0.70; in patients with a leukemia burden of >5%, the probability of event-free survival was only 0.23. CONCLUSIONS: Further improvements in vector design will help to improve the effectiveness of this treatment. It will become important to isolate factors that will make it possible to identify patients who will respond to this therapy in the long term.
Authors: Sjoerd H van der Burg; Michael Kalos; Cécile Gouttefangeas; Sylvia Janetzki; Christian Ottensmeier; Marij J P Welters; Pedro Romero; Cedrik M Britten; Axel Hoos Journal: Sci Transl Med Date: 2011-11-09 Impact factor: 17.956
Authors: Michaela Kuhlen; Andre M Willasch; Jean-Hugues Dalle; Jacek Wachowiak; Isaac Yaniv; Marianne Ifversen; Petr Sedlacek; Tayfun Guengoer; Peter Lang; Peter Bader; Sabina Sufliarska; Adriana Balduzzi; Brigitte Strahm; Irene von Luettichau; Jessica I Hoell; Arndt Borkhardt; Thomas Klingebiel; Martin Schrappe; Arend von Stackelberg; Evgenia Glogova; Ulrike Poetschger; Roland Meisel; Christina Peters Journal: Br J Haematol Date: 2017-11-28 Impact factor: 6.998
Authors: Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: Kevin A Hay; Jordan Gauthier; Alexandre V Hirayama; Jenna M Voutsinas; Qian Wu; Daniel Li; Ted A Gooley; Sindhu Cherian; Xueyan Chen; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Rachel N Steinmetz; Gary Schoch; Aude G Chapuis; Brian G Till; Hans-Peter Kiem; Jorge D Ramos; Mazyar Shadman; Ryan D Cassaday; Utkarsh H Acharya; Stanley R Riddell; David G Maloney; Cameron J Turtle Journal: Blood Date: 2019-02-06 Impact factor: 22.113
Authors: Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June Journal: N Engl J Med Date: 2013-03-25 Impact factor: 91.245
Authors: Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu Journal: Biol Blood Marrow Transplant Date: 2018-12-25 Impact factor: 5.742
Authors: Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440
Authors: Katayoun Rezvani; Sattva S Neelapu; Elizabeth J Shpall; Kris M Mahadeo; Sajad J Khazal; Hisham Abdel-Azim; Julie C Fitzgerald; Agne Taraseviciute; Catherine M Bollard; Priti Tewari; Christine Duncan; Chani Traube; David McCall; Marie E Steiner; Ira M Cheifetz; Leslie E Lehmann; Rodrigo Mejia; John M Slopis; Rajinder Bajwa; Partow Kebriaei; Paul L Martin; Jerelyn Moffet; Jennifer McArthur; Demetrios Petropoulos; Joan O'Hanlon Curry; Sarah Featherston; Jessica Foglesong; Basirat Shoberu; Alison Gulbis; Maria E Mireles; Lisa Hafemeister; Cathy Nguyen; Neena Kapoor Journal: Nat Rev Clin Oncol Date: 2019-01 Impact factor: 66.675